Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 9/20 | 0.57 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322736 | 1.00 | LMNA (0.63) | LMNAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14970717 | 0.82 | KDM4E (0.88) | LMNAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4729812 | 0.81 | LTA4H (0.79) | LTA4HHTR7HTR1ADRD2HTR6 | |
| SCHEMBL4729810 | 0.81 | LTA4H (0.79) | LTA4HHTR7HTR1ADRD2HTR6 | |
| SCHEMBL7012697 | 0.81 | KDM4E (0.84) | LMNAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14970458 | 0.80 | KDM4E (0.86) | LMNAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14359509 | 0.80 | MEN1 (0.62) | LTA4HHTR7HTR6KMT2AMEN1 | |
| SCHEMBL6847443 | 0.78 | HRH3 (0.64) | KDM4EALDH1A1LTA4HKMT2AMEN1 | |
| SCHEMBL28311408 | 0.77 | KDM4E (0.75) | LMNAHTTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8909979 | 0.77 | KDM4E (0.72) | LMNAHTTKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | LMNA 1889/4885HTT 70/4885KDM4E 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.